Physician profile
Jeff E Murad
NPI 1548230436
$2,018.00
in general payments reported to CMS, 2019-2025
14 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $113 · 2021: $485 · 2022: $165 · 2023: $379 · 2024: $301 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $719.46 | 2019-2025 | Cequa |
| Allergan, INC. | $270.43 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $213.74 | 2022-2023 | Syfovre |
| Abbvie INC. | $164.33 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $124.97 | 2024 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $116.14 | 2019 | |
| Oyster Point Pharma, INC. | $110.57 | 2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $67.46 | 2023-2024 | Vyzulta, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $63.30 | 2019-2021 | |
| Alcon Vision LLC | $63.01 | 2021-2024 | Rocklatan |
| Shire North American Group INC | $49.45 | 2019 | |
| Biotissue Holdings INC. | $23.72 | 2022 | |
| Kala Pharmaceuticals, INC. | $15.73 | 2021 | |
| Harrow Eye, LLC | $15.69 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Murad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.